These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
579 related articles for article (PubMed ID: 11719439)
41. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611 [TBL] [Abstract][Full Text] [Related]
42. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series. Gomes AL; Gouveia A; Capelinha AF; de la Cruz D; Silva P; Reis RM; Pimenta A; Lopes JM J Clin Pathol; 2008 Feb; 61(2):203-8. PubMed ID: 17827398 [TBL] [Abstract][Full Text] [Related]
43. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions. Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009 [TBL] [Abstract][Full Text] [Related]
44. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Miettinen M; Wang ZF; Lasota J Am J Surg Pathol; 2009 Sep; 33(9):1401-8. PubMed ID: 19606013 [TBL] [Abstract][Full Text] [Related]
45. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Willmore-Payne C; Layfield LJ; Holden JA Cancer; 2005 Jun; 105(3):165-70. PubMed ID: 15822120 [TBL] [Abstract][Full Text] [Related]
46. [Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype]. Wardelmann E; Pauls K; Merkelbach-Bruse S; Hrychyk A; Losen I; Hohenberger P; Büttner R; Pietsch T Verh Dtsch Ges Pathol; 2004; 88():174-83. PubMed ID: 16892550 [TBL] [Abstract][Full Text] [Related]
47. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Pauls K; Merkelbach-Bruse S; Thal D; Büttner R; Wardelmann E Histopathology; 2005 Feb; 46(2):166-75. PubMed ID: 15693889 [TBL] [Abstract][Full Text] [Related]
48. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Ali S; Ali S Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849 [TBL] [Abstract][Full Text] [Related]
49. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417 [TBL] [Abstract][Full Text] [Related]
50. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract. Hirota S; Isozaki K; Nishida T; Kitamura Y J Gastroenterol; 2000; 35 Suppl 12():75-9. PubMed ID: 10779223 [TBL] [Abstract][Full Text] [Related]
52. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. Singer S; Rubin BP; Lux ML; Chen CJ; Demetri GD; Fletcher CD; Fletcher JA J Clin Oncol; 2002 Sep; 20(18):3898-905. PubMed ID: 12228211 [TBL] [Abstract][Full Text] [Related]
53. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Lasota J; Jasinski M; Sarlomo-Rikala M; Miettinen M Am J Pathol; 1999 Jan; 154(1):53-60. PubMed ID: 9916918 [TBL] [Abstract][Full Text] [Related]
54. Cathepsin L is highly expressed in gastrointestinal stromal tumors. Miyamoto K; Iwadate M; Yanagisawa Y; Ito E; Imai J; Yamamoto M; Sawada N; Saito M; Suzuki S; Nakamura I; Ohki S; Saze Z; Kogure M; Gotoh M; Omicronbara K; Ohira H; Tasaki K; Abe M; Goshima N; Watanabe S; Waguri S; Takenoshita S Int J Oncol; 2011 Nov; 39(5):1109-15. PubMed ID: 21769426 [TBL] [Abstract][Full Text] [Related]
55. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Miettinen M; Majidi M; Lasota J Eur J Cancer; 2002 Sep; 38 Suppl 5():S39-51. PubMed ID: 12528772 [TBL] [Abstract][Full Text] [Related]
56. Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor. Yasuoka R; Sakakura C; Shimomura K; Fujita Y; Nakanishi M; Aragane H; Hagiwara A; Bamba M; Abe T; Yamagishi H Dig Surg; 2003; 20(3):183-91. PubMed ID: 12759497 [TBL] [Abstract][Full Text] [Related]
57. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Corless CL; McGreevey L; Haley A; Town A; Heinrich MC Am J Pathol; 2002 May; 160(5):1567-72. PubMed ID: 12000708 [TBL] [Abstract][Full Text] [Related]
58. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Isozaki K; Terris B; Belghiti J; Schiffmann S; Hirota S; Vanderwinden JM Am J Pathol; 2000 Nov; 157(5):1581-5. PubMed ID: 11073817 [TBL] [Abstract][Full Text] [Related]
59. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Miettinen M; Sarlomo-Rikala M; Lasota J Mod Pathol; 2000 May; 13(5):536-41. PubMed ID: 10824925 [TBL] [Abstract][Full Text] [Related]
60. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Lasota J; Kopczynski J; Sarlomo-Rikala M; Schneider-Stock R; Stachura T; Kordek R; Michal M; Boltze C; Roessner A; Stachura J; Miettinen M Hum Pathol; 2003 Dec; 34(12):1306-12. PubMed ID: 14691917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]